ABX advanced biochemical compounds GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.abx.de
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 380
- Registration Number
- NCT06122584
- Locations
- 🇪🇸
Hospital Vithas Valencia 9 de Octubre, Valencia, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
🇫🇷CHRU de Nancy, Nancy, France
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Prostate CancerProstate Cancer Recurrent
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT04742361
- Locations
- 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇳🇱RUMC, Nijmegen, Netherlands
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
Phase 3
Completed
- Conditions
- Prostate Cancer RecurrentProstate Cancer
- Interventions
- Drug: F-18-PSMA-1007Drug: F-18-Fluorocholine
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 200
- Registration Number
- NCT04102553
- Locations
- 🇫🇷
Centre Jean Perrin Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷Hôpitaux de Brabois (Vandoeuvre-les-Nancy), Nancy, France
🇫🇷Centre Léon Bérard LUMEN, Lyon, France
© Copyright 2025. All Rights Reserved by MedPath